Interim data has been selected for an oral presentation at the upcoming Lysosomal Disorder Network (LDN) WORLD Symposium being held 8-10 February 2012 in San Diego, CA, Synageva added.
The Phase I/II trial was designed to assess the safety and tolerability of SBC-102 administered weekly in patients with liver dysfunction due to late onset LAL Deficiency.
The study is fully enrolled with all patients completing their scheduled infusions. There have been no treatment-related serious adverse events, infusion-related reactions or withdrawals reported to date, and patients have begun transitioning into the extension study.
Fosun Pharma agrees XH-S004 overseas licensing deal
Itepekimab meets primary endpoint in one of two Phase 3 COPD trials
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients
Destiny Pharma launches research on XF-73 for cystic fibrosis MRSA infections
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence